InflaRx NV

As of June 17, 2025, InflaRx NV's technical trend is bearish, supported by negative MACD and Bollinger Bands signals, despite a mildly bullish KST indicator.

InflaRx NV is a clinical-stage biopharmaceutical company developing monoclonal antibodies for life-threatening inflammatory diseases, with a market cap of $51.69 million and a recent net profit of -$9 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

As of Jun 18, InflaRx NV has a market capitalization of 51.69 million, with net sales of 0.19 million and a net profit of -53.31 million over the latest four quarters. The company reported shareholder's funds of 63.60 million and total assets of 78.72 million as of Dec 24.